GlassScriptPhysician profile
Fraser D Mckay
NPI 1447668058
$5,669.44
in general payments reported to CMS, 2019-2025
25 companies · $562 in 2025
The $562 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $495 · 2021: $1,198 · 2022: $665 · 2023: $1,202 · 2024: $841 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $715.17 | 2019-2025 | Rocklatan, Simbrinza, Rhopressa |
| Allergan, INC. | $665.15 | 2019-2021 | |
| Abbvie INC. | $558.03 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $516.57 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Novartis Pharmaceuticals Corporation | $434.59 | 2019-2023 | |
| Horizon Therapeutics Plc | $378.83 | 2020-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $373.38 | 2019-2021 | |
| Amgen INC. | $243.66 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $232.61 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $226.47 | 2022-2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $206.65 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $158.07 | 2021 | |
| Eyevance Pharmaceuticals LLC | $150.33 | 2022 | |
| Oyster Point Pharma, INC. | $150.16 | 2022-2024 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $130.52 | 2024-2025 | Eylea Hd, Eylea |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $111.12 | 2022-2025 | Vyzulta, Prolensa, Xiidra |
| Dompe US, INC. | $102.73 | 2025 | Oxervate |
| Harrow Eye, LLC | $94.01 | 2024-2025 | Vevye, Iheezo, Triesence |
| Astellas Pharma US INC | $80.68 | 2023-2025 | Izervay |
| Sight Sciences, INC. | $44.73 | 2023-2024 | Omni Surgical System |
| Rxsight INC | $25.99 | 2022 | |
| Biotissue Holdings INC. | $23.92 | 2019-2025 | |
| Apellis Pharmaceuticals, INC. | $16.14 | 2024 | Syfovre |
| Ivantis, INC | $15.99 | 2020 | |
| Spark Therapeutics, INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fraser Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.